OIPE JC106 DEC 27 2002 PATENT & TRADEMARK OFFICE

| FORM PTO-1449 (REV.7-80) | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 210121.544 | APPLICATION NO. 09/930,125 |
|---|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT** *(Use several sheets if necessary)* | | APPLICANTS Susan Hand-Zimmermann et al. | |
| | | FILING DATE August 14, 2001 | GROUP ART UNIT 1635 |

RECEIVED JAN 0 2 2003 TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---|---|---|---|---|---|---|---|
| | CA | | | | | | |
| | CB | | | | | | |

## FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION YES | TRANSLATION NO |
|---|---|---|---|---|---|---|
| | CC | | | | | |
| | CD | | | | | |

## OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

| | | | |
|---|---|---|---|
| | CE | ✓ | Ishikawa, T. et al., "Amplification of the *c-erb*B-2 (HER-2/*neu*) Gene in Gastric Cancer Cells. *Detection by fluorescene* in situ *hybridization*," *Am. J. Pathol. 151*(3): 761-768, September 1997. |
| | CF | ✓ | Kast, W.M. et al., "Cooperation Between Cytotoxic and Helper T Lymphocytes in Protection Against Lethal Sendai Virus Infection. Protection by T cells in MHC-restricted and MHC-regulated; a model for MHC-Disease associations," *Journal of Experimental Medicine 164*(3): 723-738, September 1986. |
| | CG | ✓ | Keene, J.A. and Forman, J, "Helper Activity Is Required for the in vivo Generation of Cytotoxic T Lymphocytes," *Journal of Experimental Medicine 155*(3): 768-782, March 1982. |
| | CH | | Kono, K. et al., "Identification of HER2/neu-Derived Peptide Epitopes Recognized By Gastric Cancer-Specific Cytotoxic T lymphocytes," *International Journal of Cancer 78*(2): 202-208, October 5, 1998. |
| | CI | ✓ | Melief, C.J.M., "Tumor Eradication By Adoptive Transfer of Cytotoxic T Lymphocytes," *Adv. Cancer Res. 58*: 143-175, 1992. |
| | CJ | ✓ | Mumberg, D. et al., "CD4$^+$ T cells eliminate MHC class II-negative cancer cells *in vivo* by indirect effects of IFN-γ," *Proc. Natl. Acad. Sci. USA 96*: 8633-8638, July 1999. |
| | CK | | Ossendorp, F. et al., "Specific T Helper Cell Requirements for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors," *Journal of Experimental Medicine 187*(5): 693-702, March 2, 1998. |
| | CL | | Peoples, G.E. et al., "Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide," *Proc. Natl. Acad. Sci. USA 92*: 432-436, January 1995. |

| EXAMINER S. Gupta | DATE CONSIDERED 8/7/03 |
|---|---|

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

DEC 2 7 2002
PATENT & TRADEMARK OFFICE 96 SC106



| FORM PTO-1449 (REV.7-80) | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 210121.544 | APPLICATION NO. 09/930,125 |
|---|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT** *(Use several sheets if necessary)* | | APPLICANTS Susan Hand-Zimmermann et al. | |
| | | FILING DATE August 14, 2001 | GROUP ART UNIT 1635 |

RECEIVED
JAN 0 2 2003
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---|---|---|---|---|---|---|---|
| | ~~BA~~ | | | | | | |
| | BB | | | | | | |

## FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION YES | TRANSLATION NO |
|---|---|---|---|---|---|---|
| | BC | | | | | |
| | BD | | | | | |

## OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

| | | | |
|---|---|---|---|
| | BE | ✓ | Disis, M.L. et al., "Existent T-Cell and Antibody Immunity to HER-2/neu Protein in Patients with Breast Cancer," *Cancer Research 54*(1): 16-20, January 1, 1994. |
| | BF | ✓ | Donnelly, J.J et al., "DNA Vaccines," *Annual Rev. Immunol. 15*: 617-648, 1997. |
| | BG | ✓ | Esserman, L.J. et al., "Vaccination with the extracellular domain of p185$^{neu}$ prevents mammary tumor development in *neu* transgenic mice," *Cancer Immunol. Immunother. 47*(6): 337-342, 1999. |
| | BH | ✓ | Greenberg, P.D., "Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells," *Adv. Immunol. 49*: 281-355, 1991. |
| | BI | ✓ | Greenberg, P.D., "Therapy of Disseminated Murine Leukemia with Cyclophosphamide and Immune Lyt-1$^+$,2$^-$ T Cells. Tumor Eradication Does Not Require Participation of Cytotoxic T Cell," *Journal of Experimental Medicine 161*(5): 1122-1134, May 1985. |
| | BJ | ✓ | Greenberg P.D. et al., "Eradication of Disseminated Murine Leukemia By Chemoimmunotherapy with Cyclophosphamide and Adoptively Transferred Immune Syngeneic Lyt-1+2$^-$ Lymphocytes," *Journal of Experimental Medicine 154*(3): 952-963, September 1981. |
| | BK | ✓ | Hung, K. et al., "The Central Role of CD4$^+$ T Cells in the Antitumor Immune Response," *Journal of Experimental Medicine 188*(12): 2357-2368, December 21, 1998. |
| | BL | ✓ | Ioannides and Whiteside, "T Cell Recognition of Human Tumors: Implications for Molecular Immunotherapy of Cancer," *Clinical Immunology and Immunopathology 66*(2): 91-106, February 1993. |

| EXAMINER | DATE CONSIDERED |
|---|---|
| | 8/7/03 |

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

RECEIVED
JAN 0 2 2003
TECH CENTER 1600/2900

OIPE
DEC 27 2002
JC106
PATENT & TRADEMARK OFFICE

FORM PTO-1449 (REV.7-80)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT**
*(Use several sheets if necessary)*



| ATTY. DOCKET NO. | APPLICATION NO. |
|---|---|
| 210121.544 | 09/930,125 |
| **APPLICANTS** | |
| Susan Hand-Zimmermann et al. | |
| **FILING DATE** | **GROUP ART UNIT** |
| August 14, 2001 | 1635 |

## U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---|---|---|---|---|---|---|---|
| | DA | | | | | | |
| | DB | | | | | | |
| | | | | | | | |

## FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION YES | TRANSLATION NO |
|---|---|---|---|---|---|---|
| | DC | | | | | |
| | DD | | | | | |
| | | | | | | |

## OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

| | | |
|---|---|---|
| | DE | Pupa, S.M. et al., "Antibody Response against the *c-erb*B-2 Oncoprotein in Breast Carcinoma Patients," *Cancer Research 53*(24): 5864-5866, December 15, 1993. |
| | DF | Raz, E. et al., "Preferential induction of a $Th_1$ immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization," *Proc. Natl. Acad. Sci. USA 93*: 5141-5145, May 1996. |
| | DG | Semba, K. et al., "A v-*erb*B-related protooncogene, c-*erb*B-2, is distinct from the c-*erbB-1*/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma," *Proc. Natl. Acad. Sci. USA 82*(19): 6497-6501, October 1985. |
| | DH | Slamon, D.J. et al., "Studies of the HER-2/*neu* Proto-oncogene in Human Breast and Ovarian Cancer," *Science 244*(4905): 707-712, May 12, 1989. |
| | DI | Tuttle, T.M. et al., "Proliferative and Cytokine Responses to Class II HER-2/neu-associated Peptides in Breast Cancer Patients," *Clinical Cancer Research 4*(8): 2015-2024, August 1998. |
| | DJ | Wei, W.Z. et al., "Protection Against Mammary Tumor Growth By Vaccination with Full-Length, Modified Human *ErbB-2* DNA," *International Journal of Cancer 81*(5): 748-754, May 31, 1999. |
| | DK | Weiner, L.M., "Monoclonal Antibody Therapy of Cancer," *Semin. Oncol. 26*(5 Suppl 14): 43-51, October 1999. |
| | DL | |

| EXAMINER | DATE CONSIDERED |
|---|---|
| | 8/7/03 |

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

#6 I.D.S.

Sheet 1 of 4

DEC 27 2002 PATENT & TRADEMARK OFFICE TC1600

RECEIVED JAN 02 2003 TECH CENTER 1600/2900

FORM PTO-1449 (REV. 7-80)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 210121.544

APPLICATION NO. 09/930,125

APPLICANTS Susan Hand-Zimmermann et al.

FILING DATE August 14, 2001

GROUP ART UNIT 1635

## INFORMATION DISCLOSURE STATEMENT

*(Use several sheets if necessary)*

### U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---|---|---|---|---|---|---|---|
| | AA | 5,801,005 | 09/01/98 | Cheever et al. | 435 | 7.24 | |
| | AB | | | | | | |

### FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION YES | TRANSLATION NO |
|---|---|---|---|---|---|---|
| | AC | WO 93/14781 | 08/05/93 | WIPO | | |
| | AD | WO 99/45954 | 09/16/99 | WIPO | | |
| | AE | WO 99/57981 | 11/18/99 | WIPO | | |
| | AF | WO 00/44899 | 08/03/00 | WIPO | | |

### OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

| | | |
|---|---|---|
| | AG | Amici, A. et al., "Genetic immunization against *neu/erbB2* transgenic breast cancer," *Cancer Immunol. Immunother. 47*(4): 183-190, 1998. |
| | AH | Chen, Y. et al., "DNA Vaccines Encoding Full-Length or Truncated Neu Induce Protective Immunity against Neu-expressing Mammary Tumors," *Cancer Research 58*(9): 1965-1971, 1998. Comments in: *Cancer Research 59*(17): 4471-4472, 1999. |
| | AI | Clay, T.M. et al., "Efficient Transfer of a Tumor Antigen-Reactive TCR to Human Peripheral Blood Lymphocytes Confers Anti-Tumor Reactivity," *Journal of Immunology 163*: 507-513, 1999. |
| | AJ | Cooper, L.J.N. et al, "Transfer of Specificity for Human Immunodeficiency Virus Type 1 into Primary Human T Lymphocytes by Introduction of T-Cell Receptor Genes," *Journal of Virology 74*(17): 8207-8212, September 2000. |
| | AK | Coussens, L. et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with *neu* Oncogene," *Science 230*(4730): 1132-1139, December 6, 1985. |
| | AL | Disis, M.L. et al., "High-Titer HER-2/*neu* Protein-Specific Antibody Can Be Detected in Patients With Early-Stage Breast Cancer," *Journal of Clinical Oncology 15*(11): 3363-3367, November 1997. |

EXAMINER

DATE CONSIDERED 8/7/03

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

F:\Pat\P7-27.doc